When the supply chain fails the patient

The Hill reports that millions of bottles of eye-drop medication — products widely used to treat allergies and inflammation — have been recalled nationwide after the Food and Drug Administration identified a potential foreign substance in the supply. The story is brief. The principle it illustrates is not.

Consider what a consumer buying a bottle of eye drops actually knows: the name on the label, perhaps the price, perhaps a friend's recommendation. She cannot inspect the manufacturing line, audit the clean-room protocols, or test each batch for contamination. This is not ignorance born of carelessness; it is the structural condition of a complex division of labor. The very specialization that makes modern medicine affordable — components sourced from dozens of facilities, assembled and packaged along chains that span continents — is the same specialization that makes individual oversight impossible. Each worker knows her task; no single buyer can know them all.

I argued in The Wealth of Nations that the division of labor is the great engine of productive power, but I was equally clear that it creates dependencies which only institutions can manage. Where the individual cannot inspect, the sovereign must. Where private interest might be tempted to conceal a defect rather than bear the cost of a recall, a credible public authority — one that can compel disclosure and impose penalties — is not an interference with the market but a precondition of it. Without the FDA's standing power to issue recalls, the consumer's only remedy would be after the injury, which is no remedy at all for the person who has already lost her sight.

Notice also what a recall, done well, actually demonstrates. It is not evidence that the market has failed in some fundamental sense — it is evidence that the disciplinary institution is functioning. The manufacturer is exposed; the product is withdrawn; the consumer is warned. This is precisely the transparency that honest exchange requires. The question worth asking — and here I mark this as inference, not recollection, since the story does not say — is whether the recall came swiftly enough, and whether the regulator had the resources and independence to act without pressure from the firms it oversees. A captured regulator is no regulator at all; it is merely a seal of approval rented to the highest bidder.

The deeper moral point is one I drew from sympathy rather than from ledgers. Commerce depends on a degree of trust between strangers — the buyer trusts that the seller has represented the goods honestly, the seller trusts that the buyer will honor the agreed price. In ordinary trade, repeated dealing and reputation help sustain that trust. But a patient buying medicine from a national supply chain has no ongoing relationship with the manufacturer; she cannot punish defection by withdrawing future custom in any way the producer would feel. This is precisely where public institutions must substitute for the personal bonds that govern smaller markets. The FDA, in other words, is not the enemy of commerce in medicine — it is the institutional substitute for the trust that scale and anonymity have otherwise dissolved.

The lesson, then, is not that markets in medicine are uniquely corrupt, nor that producers are uniquely villainous. It is that every market rests on a framework, and the framework must be adequate to the complexity of the trade it governs. As supply chains grow longer and more intricate, the institutions of consumer protection must grow more capable alongside them — better funded, better staffed, and, above all, insulated from the mercantile interest they are charged with disciplining. That is the standing challenge, and a recalled bottle of eye drops is as good a reminder of it as any.